{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T19:34:33Z","timestamp":1785267273238,"version":"3.55.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Klinikum der Universit\u00e4t M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Prediction of response to checkpoint inhibition (ICI) and immune related adverse events (irAEs) remain a challenge in the immunotherapy of solid tumors. To better understand the real-world clinical courses under ICI and identify possible predictive markers for response and irAEs, we retrospectively collected and analysed data from our interdisciplinary CCCMunich\n                    <jats:sup>\n                      <jats:bold>\n                        <jats:italic>LMU<\/jats:italic>\n                      <\/jats:bold>\n                    <\/jats:sup>\n                    outpatient clinic. We analysed the clinical course, standard laboratory parameters and staging results of 342 patients who received ICI therapy in the interdisciplinary outpatient clinic of the CCCMunich\n                    <jats:sup>\n                      <jats:bold>\n                        <jats:italic>LMU<\/jats:italic>\n                      <\/jats:bold>\n                    <\/jats:sup>\n                    between January 2015 and November 2020. Initial response to ICI was defined as complete response, partial response, stable disease or mixed response with treatment continuation in the second radiologic staging after start of therapy. Median age of the included patients was 67\u00a0years (25\u201389). More male patients received ICI on our outpatient ward than female patients (67.8% vs. 32.2%). The most common entities were urothelial carcinoma (21.3%) and bronchial carcinoma (19.6%), followed by renal cell carcinoma (18.7%), and head and neck tumors (10.8%). 24.6% of patients were initial responders. Patients who did not respond to ICI therapy had lower leukocyte, lymphocyte, monocyte, and neutrophil counts before treatment start compared to initial responders. The consolidation of these laboratory parameters into a score could not accurately predict initial response or progression-free survival (PFS). IrAEs occurred in approximately one-third of all included patients. The main side effects in patients expierencing irAEs were thyroiditis (20.5%), pneumonitis (16.4%), hepatitis (15.8%), and dermatological side effects (11.0%). Patients experiencing irAEs had a significantly longer PFS than patients without irAEs. Side effects were more frequent and severe in patients treated with combined ICI. Autoimmune disorders were not associated with more frequent occurrence of irAEs. This retrospective analysis illustrates the real-world use of ICI in clinical practice. With only 24.6% of patients responding to ICI, the clinical need for predictive markers is obvious and standard laboratory parameters such as white blood cell counts may become part of a comprehensive score to predict response and adverse events.\n                  <\/jats:p>","DOI":"10.1038\/s41598-025-30220-0","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T06:35:14Z","timestamp":1765175714000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Real-world analysis of immune checkpoint inhibitor efficacy and response predictors in patients treated at the CCCMunichLMU outpatient clinic"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2503-5851","authenticated-orcid":false,"given":"Klara","family":"Dorman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kilian","family":"Breitenwieser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danmei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Probst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Heinrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang G.","family":"Kunz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian W.","family":"Holch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Gie\u00dfen-Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Boeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"von Bergwelt-Baildon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timotheus","family":"Landfarth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Hornung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jozefina","family":"Casuscelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Berger-Th\u00fcrmel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Heinemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Benedikt","family":"Westphalen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Reischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,8]]},"reference":[{"key":"30220_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12040764","author":"Z Guo","year":"2024","unstructured":"Guo, Z., Yu, J., Chen, Z., Chen, S. & Wang, L. Immunological mechanisms behind anti-pd-1\/pd-l1 immune checkpoint blockade: Intratumoral reinvigoration or systemic induction?. Biomedicines https:\/\/doi.org\/10.3390\/biomedicines12040764 (2024).","journal-title":"Biomedicines"},{"key":"30220_CR2","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","volume":"33","author":"J Haanen","year":"2022","unstructured":"Haanen, J. et al. Management of toxicities from immunotherapy: Esmo clinical practice guideline for diagnosis, treatment and follow-up*. Ann. Oncol. 33, 1217\u20131238. https:\/\/doi.org\/10.1016\/j.annonc.2022.10.001 (2022).","journal-title":"Ann. Oncol."},{"key":"30220_CR3","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang, D. Y. et al. Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis. JAMA Oncol. 4, 1721\u20131728. https:\/\/doi.org\/10.1001\/jamaoncol.2018.3923 (2018).","journal-title":"JAMA Oncol."},{"key":"30220_CR4","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1002\/cncr.32468","volume":"126","author":"JN Bodor","year":"2020","unstructured":"Bodor, J. N., Boumber, Y. & Borghaei, H. Biomarkers for immune checkpoint inhibition in non-small cell lung cancer (nsclc). Cancer 126, 260\u2013270. https:\/\/doi.org\/10.1002\/cncr.32468 (2020).","journal-title":"Cancer"},{"key":"30220_CR5","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.cell.2021.01.002","volume":"184","author":"K Litchfield","year":"2021","unstructured":"Litchfield, K. et al. Meta-analysis of tumor- and t cell-intrinsic mechanisms of sensitization to checkpoint inhibition. Cell 184, 596-614.e514. https:\/\/doi.org\/10.1016\/j.cell.2021.01.002 (2021).","journal-title":"Cell"},{"key":"30220_CR6","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.semcancer.2021.03.036","volume":"79","author":"B Shum","year":"2022","unstructured":"Shum, B., Larkin, J. & Turajlic, S. Predictive biomarkers for response to immune checkpoint inhibition. Seminars Cancer Biol. 79, 4\u201317. https:\/\/doi.org\/10.1016\/j.semcancer.2021.03.036 (2022).","journal-title":"Seminars Cancer Biol."},{"key":"30220_CR7","doi-asserted-by":"publisher","first-page":"e196879","DOI":"10.1001\/jamanetworkopen.2019.6879","volume":"2","author":"Y Yu","year":"2019","unstructured":"Yu, Y. et al. Association of survival and immune-related biomarkers with immunotherapy in patients with non-small cell lung cancer: A meta-analysis and individual patient-level analysis. JAMA Netw. Open 2, e196879\u2013e196879. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.6879 (2019).","journal-title":"JAMA Netw. Open"},{"key":"30220_CR8","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar3593","author":"R Cristescu","year":"2018","unstructured":"Cristescu, R. et al. Pan-tumor genomic biomarkers for pd-1 checkpoint blockade-based immunotherapy. Science https:\/\/doi.org\/10.1126\/science.aar3593 (2018).","journal-title":"Science"},{"key":"30220_CR9","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1158\/1078-0432.Ccr-15-1678","volume":"22","author":"JC Dudley","year":"2016","unstructured":"Dudley, J. C., Lin, M. T., Le, D. T. & Eshleman, J. R. Microsatellite instability as a biomarker for pd-1 blockade. Clin. Cancer Res. 22, 813\u2013820. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-15-1678 (2016).","journal-title":"Clin. Cancer Res."},{"key":"30220_CR10","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","volume":"51","author":"RM Samstein","year":"2019","unstructured":"Samstein, R. M. et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat. Genet. 51, 202\u2013206. https:\/\/doi.org\/10.1038\/s41588-018-0312-8 (2019).","journal-title":"Nat. Genet."},{"key":"30220_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.585311","author":"JW Hommes","year":"2021","unstructured":"Hommes, J. W., Verheijden, R. J., Suijkerbuijk, K. P. M. & Hamann, D. Biomarkers of checkpoint inhibitor induced immune-related adverse events\u2014A comprehensive review. Front. Oncol. https:\/\/doi.org\/10.3389\/fonc.2020.585311 (2021).","journal-title":"Front. Oncol."},{"key":"30220_CR12","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1093\/annonc\/mdw443","volume":"28","author":"AM Menzies","year":"2017","unstructured":"Menzies, A. M. et al. Anti-pd-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann. Oncol. 28, 368\u2013376. https:\/\/doi.org\/10.1093\/annonc\/mdw443 (2017).","journal-title":"Ann. Oncol."},{"key":"30220_CR13","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1200\/jco.2017.77.0305","volume":"36","author":"GC Leonardi","year":"2018","unstructured":"Leonardi, G. C. et al. Safety of programmed death-1 pathway inhibitors among patients with non-small-cell lung cancer and preexisting autoimmune disorders. J. Clin. Oncol. 36, 1905\u20131912. https:\/\/doi.org\/10.1200\/jco.2017.77.0305 (2018).","journal-title":"J. Clin. Oncol."},{"issue":"45","key":"30220_CR14","first-page":"1","volume":"12","author":"S Van Buuren","year":"2011","unstructured":"Van Buuren, S. & Groothuis-Oudshoorn, K. Mice: Multivariate imputation by chained equations in r. J. Stat. Softw. 12(45), 1\u201367 (2011).","journal-title":"J. Stat. Softw."},{"key":"30220_CR15","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1002\/sim.3177","volume":"27","author":"AM Wood","year":"2008","unstructured":"Wood, A. M., White, I. R. & Royston, P. How should variable selection be performed with multiply imputed data?. Stat. Med. 27, 3227\u20133246. https:\/\/doi.org\/10.1002\/sim.3177 (2008).","journal-title":"Stat. Med."},{"key":"30220_CR16","doi-asserted-by":"publisher","first-page":"7857","DOI":"10.1038\/s41598-021-82810-3","volume":"11","author":"W Cheng","year":"2021","unstructured":"Cheng, W., Hornung, R., Xu, K., Yang, C. H. & Li, J. Complement c3 identified as a unique risk factor for disease severity among young Covid-19 patients in Wuhan, China. Sci. Rep. 11, 7857. https:\/\/doi.org\/10.1038\/s41598-021-82810-3 (2021).","journal-title":"Sci. Rep."},{"key":"30220_CR17","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s12874-016-0239-7","volume":"16","author":"S Wahl","year":"2016","unstructured":"Wahl, S., Boulesteix, A.-L., Zierer, A., Thorand, B. & van de Wiel, M. A. Assessment of predictive performance in incomplete data by combining internal validation and multiple imputation. BMC Med. Res. Methodol. 16, 144. https:\/\/doi.org\/10.1186\/s12874-016-0239-7 (2016).","journal-title":"BMC Med. Res. Methodol."},{"key":"30220_CR18","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","volume":"11","author":"C Robert","year":"2020","unstructured":"Robert, C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat. Commun. 11, 3801. https:\/\/doi.org\/10.1038\/s41467-020-17670-y (2020).","journal-title":"Nat. Commun."},{"key":"30220_CR19","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2217\/imt-2023-0158","volume":"16","author":"X Zhao","year":"2024","unstructured":"Zhao, X. et al. Imaging findings can\u2019t mean everything in the era of immunotherapy: A case report and literature review. Immunotherapy 16, 99\u2013106. https:\/\/doi.org\/10.2217\/imt-2023-0158 (2024).","journal-title":"Immunotherapy"},{"key":"30220_CR20","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.cell.2015.03.030","volume":"161","author":"P Sharma","year":"2015","unstructured":"Sharma, P. & Allison, J. P. Immune checkpoint targeting in cancer therapy: Toward combination strategies with curative potential. Cell 161, 205\u2013214. https:\/\/doi.org\/10.1016\/j.cell.2015.03.030 (2015).","journal-title":"Cell"},{"key":"30220_CR21","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1097\/JTO.0000000000000074","volume":"9","author":"S Champiat","year":"2014","unstructured":"Champiat, S. et al. Incorporating immune-checkpoint inhibitors into systemic therapy of nsclc. J. Thoracic Oncol. 9, 144\u2013153. https:\/\/doi.org\/10.1097\/JTO.0000000000000074 (2014).","journal-title":"J. Thoracic Oncol."},{"key":"30220_CR22","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1002\/cam4.3617","volume":"10","author":"V Noronha","year":"2021","unstructured":"Noronha, V. et al. A real-world data of immune checkpoint inhibitors in solid tumors from India. Cancer Med. 10, 1525\u20131534. https:\/\/doi.org\/10.1002\/cam4.3617 (2021).","journal-title":"Cancer Med."},{"issue":"3","key":"30220_CR23","doi-asserted-by":"publisher","first-page":"468","DOI":"10.4103\/crst.crst_185_22","volume":"5","author":"VM Patil","year":"2022","unstructured":"Patil, V. M. et al. Nivolumab in platinum-refractory head-and-neck cancers: A retrospective observational audit from a tertiary cancer center. Cancer Res. Stat. Treatment. 5(3), 468\u2013473. https:\/\/doi.org\/10.4103\/crst.crst_185_22 (2022).","journal-title":"Cancer Res. Stat. Treatment."},{"key":"30220_CR24","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1001\/jamaoncol.2018.5904","volume":"5","author":"CJD Wallis","year":"2019","unstructured":"Wallis, C. J. D. et al. Association of patient sex with efficacy of immune checkpoint inhibitors and overall survival in advanced cancers: A systematic review and meta-analysis. JAMA Oncol. 5, 529\u2013536. https:\/\/doi.org\/10.1001\/jamaoncol.2018.5904 (2019).","journal-title":"JAMA Oncol."},{"key":"30220_CR25","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.it.2019.04.002","volume":"40","author":"KE Pauken","year":"2019","unstructured":"Pauken, K. E., Dougan, M., Rose, N. R., Lichtman, A. H. & Sharpe, A. H. Adverse events following cancer immunotherapy: Obstacles and opportunities. Trends Immunol. 40, 511\u2013523. https:\/\/doi.org\/10.1016\/j.it.2019.04.002 (2019).","journal-title":"Trends Immunol."},{"issue":"10","key":"30220_CR26","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","volume":"28","author":"L Khoja","year":"2017","unstructured":"Khoja, L., Day, D., Chen, T. W., Siu, L. L. & Hansen, A. R. Tumour-and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: A systematic review. Ann. Oncol. 28(10), 2377\u20132385. https:\/\/doi.org\/10.1093\/annonc\/mdx286 (2017).","journal-title":"Ann. Oncol."},{"key":"30220_CR27","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","volume":"377","author":"JD Wolchok","year":"2017","unstructured":"Wolchok, J. D. et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 377, 1345\u20131356. https:\/\/doi.org\/10.1056\/NEJMoa1709684 (2017).","journal-title":"N. Engl. J. Med."},{"key":"30220_CR28","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","volume":"54","author":"JM Michot","year":"2016","unstructured":"Michot, J. M. et al. Immune-related adverse events with immune checkpoint blockade: A comprehensive review. Eur. J. Cancer 54, 139\u2013148. https:\/\/doi.org\/10.1016\/j.ejca.2015.11.016 (2016).","journal-title":"Eur. J. Cancer"},{"key":"30220_CR29","doi-asserted-by":"publisher","first-page":"12253","DOI":"10.1002\/cam4.5919","volume":"12","author":"T Mehra","year":"2023","unstructured":"Mehra, T. et al. Pre-treatment comorbidities, c-reactive protein and eosinophil count, and immune-related adverse events as predictors of survival with checkpoint inhibition for multiple tumour entities. Cancer Med. 12, 12253\u201312262. https:\/\/doi.org\/10.1002\/cam4.5919 (2023).","journal-title":"Cancer Med."},{"key":"30220_CR30","doi-asserted-by":"publisher","first-page":"121","DOI":"10.7326\/m17-2073","volume":"168","author":"N Abdel-Wahab","year":"2018","unstructured":"Abdel-Wahab, N., Shah, M., Lopez-Olivo, M. A. & Suarez-Almazor, M. E. Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: A systematic review. Ann. Intern. Med. 168, 121\u2013130. https:\/\/doi.org\/10.7326\/m17-2073 (2018).","journal-title":"Ann. Intern. Med."},{"key":"30220_CR31","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41584-022-00841-0","volume":"18","author":"A Tison","year":"2022","unstructured":"Tison, A., Garaud, S., Chiche, L., Cornec, D. & Kostine, M. Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases. Nat. Rev. Rheumatol. 18, 641\u2013656. https:\/\/doi.org\/10.1038\/s41584-022-00841-0 (2022).","journal-title":"Nat. Rev. Rheumatol."},{"key":"30220_CR32","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1080\/07853890.2022.2070660","volume":"54","author":"C Minichsdorfer","year":"2022","unstructured":"Minichsdorfer, C., Gleiss, A., Aretin, M. B., Schmidinger, M. & Fuereder, T. Serum parameters as prognostic biomarkers in a real world cancer patient population treated with anti pd-1\/pd-l1 therapy. Ann. Med. 54, 1339\u20131349. https:\/\/doi.org\/10.1080\/07853890.2022.2070660 (2022).","journal-title":"Ann. Med."},{"key":"30220_CR33","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s00262-014-1528-9","volume":"63","author":"S Kelderman","year":"2014","unstructured":"Kelderman, S. et al. Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Cancer Immunol. Immunother. 63, 449\u2013458. https:\/\/doi.org\/10.1007\/s00262-014-1528-9 (2014).","journal-title":"Cancer Immunol. Immunother."},{"key":"30220_CR34","doi-asserted-by":"publisher","first-page":"5857","DOI":"10.21873\/anticanres.12030","volume":"37","author":"Y Taniguchi","year":"2017","unstructured":"Taniguchi, Y. et al. Predictive factors for poor progression-free survival in patients with non-small cell lung cancer treated with nivolumab. Anticancer Res. 37, 5857\u20135862. https:\/\/doi.org\/10.21873\/anticanres.12030 (2017).","journal-title":"Anticancer Res."},{"key":"30220_CR35","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004688","author":"M Hwang","year":"2022","unstructured":"Hwang, M. et al. Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy. J. Immunother. Cancer https:\/\/doi.org\/10.1136\/jitc-2022-004688 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"30220_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14215297","author":"Y Guo","year":"2022","unstructured":"Guo, Y., Xiang, D., Wan, J., Yang, L. & Zheng, C. Focus on the dynamics of neutrophil-to-lymphocyte ratio in cancer patients treated with immune checkpoint inhibitors: A meta-analysis and systematic review. Cancers https:\/\/doi.org\/10.3390\/cancers14215297 (2022).","journal-title":"Cancers"},{"key":"30220_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03398-5","author":"S-K Yoo","year":"2025","unstructured":"Yoo, S.-K. et al. Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-024-03398-5 (2025).","journal-title":"Nat. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-30220-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-30220-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-30220-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T23:01:35Z","timestamp":1765580495000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-30220-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,8]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["30220"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-30220-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,8]]},"assertion":[{"value":"1 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"KD reports honoraria from AstraZeneca and support for travel, accommodation, and expenses from Servier, GSK, Bristol Myers Squibb, and AstraZeneca. DZ has received travel support from AstraZeneca, Amgen, and BMS, as well as honoraria from AstraZeneca. LW has received honoraria from Roche and Servier, as well as support for travel from Amgen and Merck. SB reports honoraria from Servier and MSD, fees for consultancy or advisory roles from Servier, AstraZeneca, MSD, Otsuka Pharma, and Bristol Myers Squibb, and support for travel, accommodation, and expenses from Lilly. MvB has received research support from and serves on the speakers\u2019 bureau at Gilead, Miltenyi Biotec, MSD Sharpe & Dohme, Roche, Mologen, Novartis, Astellas, and BMS. VH reports research funding paid to his institution from Merck, Amgen, and Roche, fees for consultancy and advisory roles from Merck, Amgen, Roche, MSD, Bristol Myers Squibb, MSD Oncology, Novartis, Pierre Fabre, TERUMO, GSK, Servier\/Pfizer, AstraZeneca, Oncosil, and Nordic Bioscience, honoraria from Roche, Amgen, Sanofi, Merck, Servier, Pfizer, Pierre Fabre, AstraZeneca, MSD, and Seagen, and support for travel, accommodation, and expenses from Merck. CBW has received honoraria from AstraZeneca, Amgen, Bayer, BMS, Chugai, Celgene, Falk, GSK, Lilly, MSD, Merck, Janssen, Ipsen, QuiP GmbH, Roche, Servier, SIRTeX, Taiho; served on advisory boards for AstraZeneca, Bayer, BMS, Celgene, Janssen, MSD, Servier, Shire\/Baxalta, Rafael Pharmaceuticals, RedHill, Roche, has received travel support by AstraZeneca, Bayer, Celgene, Janssen, MSD, RedHill, Roche, Servier, Taiho and research grants (institutional) by Roche; is a Journal of Cancer Research and Clinical Oncology editorial board member; serves as faculty for European Society of Medical Oncology (ESMO), Deutsche Krebshilfe (DKH) and Arbeitsgemeinschaft internistische Onkologie (AIO), is a member of the EU Commission expert group: Mission Board for cancer, is a member of the BFTR steering committee: Strategiekreis Dekade gegen Krebs.. AR reports honoraria from Beigene and support for travel, accommodation, and expenses from Beigene. KB, LF, VP, KH, WGZ, JWH, CGJ, MH, TL, RH, JC and KBT have no competing interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Due to the retrospective nature of the study, the local ethics committee of the Ludwig-Maximilians-University Munich waived the need of obtaining informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"This retrospective chart review study involving human participants was in accordance with the principles of the Declaration of Helsinki and its later amendments. The study has been approved by the local ethics committee of the Ludwig-Maximilians-University Munich (project number 20-1161).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"43269"}}